Update on the treatment and prevention of ischaemic stroke

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Stroke continues to have a devastating impact on public health. Recent epidemiological studies suggest that stroke is becoming more common, perhaps due to the ageing of the population and increased survival of patients with cardiac disease. There are specific and well-defined risk factors in patients with stroke, the most important being hypertension. Treatment options to reverse the effect of acute ischaemic stroke are limited. The only approved therapy is intravenous tissue plasminogen activator (tPA). The disadvantage of tPA treatment is a rate of symptomatic haemorrhage of about 6%. Newer stroke prevention options are currently being investigated including statins, oestrogen, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). The challenge for physicians is to select the most effective intervention, and this depends on our knowledge of the underlying stroke mechanism and the patient's risk factors.

Original languageEnglish (US)
Pages (from-to)438-441
Number of pages4
JournalCurrent Medical Research and Opinion
Volume19
Issue number5
DOIs
StatePublished - 2003

Fingerprint

Stroke
Tissue Plasminogen Activator
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Epidemiologic Studies
Heart Diseases
Estrogens
Public Health
Hemorrhage
Hypertension
Physicians
Survival
Population

Keywords

  • Angiotensin receptor blockers
  • Cerebrovascular disease
  • Hypertension
  • Ischaemic stroke
  • Tissue plasminogen activators

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Update on the treatment and prevention of ischaemic stroke. / Alberts, Mark J.

In: Current Medical Research and Opinion, Vol. 19, No. 5, 2003, p. 438-441.

Research output: Contribution to journalArticle

@article{02827a4d2a464aa2b6919fc7af399050,
title = "Update on the treatment and prevention of ischaemic stroke",
abstract = "Stroke continues to have a devastating impact on public health. Recent epidemiological studies suggest that stroke is becoming more common, perhaps due to the ageing of the population and increased survival of patients with cardiac disease. There are specific and well-defined risk factors in patients with stroke, the most important being hypertension. Treatment options to reverse the effect of acute ischaemic stroke are limited. The only approved therapy is intravenous tissue plasminogen activator (tPA). The disadvantage of tPA treatment is a rate of symptomatic haemorrhage of about 6{\%}. Newer stroke prevention options are currently being investigated including statins, oestrogen, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). The challenge for physicians is to select the most effective intervention, and this depends on our knowledge of the underlying stroke mechanism and the patient's risk factors.",
keywords = "Angiotensin receptor blockers, Cerebrovascular disease, Hypertension, Ischaemic stroke, Tissue plasminogen activators",
author = "Alberts, {Mark J.}",
year = "2003",
doi = "10.1185/030079903125001956",
language = "English (US)",
volume = "19",
pages = "438--441",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Update on the treatment and prevention of ischaemic stroke

AU - Alberts, Mark J.

PY - 2003

Y1 - 2003

N2 - Stroke continues to have a devastating impact on public health. Recent epidemiological studies suggest that stroke is becoming more common, perhaps due to the ageing of the population and increased survival of patients with cardiac disease. There are specific and well-defined risk factors in patients with stroke, the most important being hypertension. Treatment options to reverse the effect of acute ischaemic stroke are limited. The only approved therapy is intravenous tissue plasminogen activator (tPA). The disadvantage of tPA treatment is a rate of symptomatic haemorrhage of about 6%. Newer stroke prevention options are currently being investigated including statins, oestrogen, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). The challenge for physicians is to select the most effective intervention, and this depends on our knowledge of the underlying stroke mechanism and the patient's risk factors.

AB - Stroke continues to have a devastating impact on public health. Recent epidemiological studies suggest that stroke is becoming more common, perhaps due to the ageing of the population and increased survival of patients with cardiac disease. There are specific and well-defined risk factors in patients with stroke, the most important being hypertension. Treatment options to reverse the effect of acute ischaemic stroke are limited. The only approved therapy is intravenous tissue plasminogen activator (tPA). The disadvantage of tPA treatment is a rate of symptomatic haemorrhage of about 6%. Newer stroke prevention options are currently being investigated including statins, oestrogen, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). The challenge for physicians is to select the most effective intervention, and this depends on our knowledge of the underlying stroke mechanism and the patient's risk factors.

KW - Angiotensin receptor blockers

KW - Cerebrovascular disease

KW - Hypertension

KW - Ischaemic stroke

KW - Tissue plasminogen activators

UR - http://www.scopus.com/inward/record.url?scp=0042233619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042233619&partnerID=8YFLogxK

U2 - 10.1185/030079903125001956

DO - 10.1185/030079903125001956

M3 - Article

C2 - 13678483

AN - SCOPUS:0042233619

VL - 19

SP - 438

EP - 441

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 5

ER -